E2086 / Eisai - LARVOL DELTA

E2086, a Selective Orexin Receptor-2 Agonist, Study for Promoting Wakefulness in Patients With Narcolepsy Type-1 (WSS 2025) - "Materials and E2086-A001-101 was a multicenter, randomized, double-blind, double-dummy, single-dose, 5-period crossover study evaluating the efficacy, safety, and tolerability of three dose strengths of E2086 compared with placebo (PBO) and modafinil in adult subjects with NT1. These data demonstrate that E2086 has the potential to improve daytime wakefulness in patients with NT1. The efficacy/safety profile supports continued investigation of E2086 in the narcolepsy patient population."

Clinical • Cataplexy • Narcolepsy • Sleep Disorder

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1 (clinicaltrials.gov) - P1 | N=22 | Completed | Sponsor: Eisai Inc. | Active, not recruiting ➔ Completed | N=40 ➔ 22

Enrollment change • Trial completion • Narcolepsy • Sleep Disorder

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1 (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Eisai Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Narcolepsy • Sleep Disorder

A Study of E2086 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Eisai Inc. | Recruiting ➔ Completed

Trial completion

A Study of E2086 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1 (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Narcolepsy • Sleep Disorder

A Study of E2086 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Eisai Inc.

New P1 trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1 (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Eisai Inc.

New P1 trial • Narcolepsy • Sleep Disorder

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants (clinicaltrials.gov) - P1 | N=53 | Completed | Sponsor: Eisai Inc. | Recruiting ➔ Completed

Trial completion

E2086, a novel selective Orexin-2 receptor agonist (WSS 2023) - No abstract available

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Eisai Inc.

New P1 trial